Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sofosbuvir,Velpatasvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ACTG Announces Publication of Pivotal Hepatitis C Study in Clinical Infectious Diseases
Details : ACTG 5360 is a combination of sofosbuvir which is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, whereas velpatasvir is an inhibitor of the HCV NS5A protein, both required for viral replication. Currently being studied for chronic hepatitis C...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 23, 2023
Lead Product(s) : Sofosbuvir,Velpatasvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Velpatasvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Ministry of Health, Brazil | State Secretary of Health of Rio Grande do Sul | TelessaúdeRS / UFRGS
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 31, 2019
Lead Product(s) : Velpatasvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Ministry of Health, Brazil | State Secretary of Health of Rio Grande do Sul | TelessaúdeRS / UFRGS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Velpatasvir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2013
Lead Product(s) : Velpatasvir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Velpatasvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 26, 2013
Lead Product(s) : Velpatasvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Velpatasvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 04, 2012
Lead Product(s) : Velpatasvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable